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Radioimmunoassay of urinary antidiuretic hormone in man:
Stimulation-suppression tests. Urinary vasopression (AVP) has
been measured in human beings by a sensitive and reproducible
radioimmunoassay. An orally administered water load (15 ml!
kg) in dehydrated normal subjects increases CHQO from — 1.4
0.1 to 2.5±0,6 mi/mm while urinary AVP decreases from
7.82± 1.56 to 2.69± 0.40 ng/2 hr. Infusion of hypertonic saline
decreases C20 from —1.8±0.3 to —2,2±O.3m1/min and
increases urinary AVP from 8.24± 2.75 to 20.28 1.94 ng/2 hr.
The correlation between all the observed values for CH2O and
urinary AVP is highly significant (r= —0.66, N= 26, P <0.001).
The correlation between plasma osmolality and urinary AVP is
also significant (r=0.62, N=26, P<0.001). According to this
equation, AVP begins to appear in urine for a plasma osmolality
of 275.2 mOsm/kg. During infusion of hypertonic saline, plasma
renin (PRA) and plasma aldosterone (PA) have been measured
by radioimmunoassays. While hypertonic saline infusion stimu-
lates vasopressin release, it decreases PRA and PA. AVP excre-
tion as measured by radioimmunoassay of urinary AVP responds
to alterations in plasma osmolality which affect AVP release,
and is an effective and precise means of assessing neurophyseal
function in man. Variations in renin secretion and AVP release
are dissociated during hypertonic saline load.
Dosage radioimmunologique de l'hormone antidiuretique
urinaire chez l'homme: Tests de stimulation-freination. L'arginine
vasopressine urinaire (AVP) a été dosée chez l'homme par une
méthode radioimmunologique sensible et reproductible. Une
charge en eau (15 mI/kg) chez des sujets déshydratés augmente
C20 de —1,4 0,1 a 2.5 0,6 mi/mm et diminue I'AVP urinaire
de 7,82± 1,56 a 2,69±0,40 ng/2 hr. La perfusion de serum sale
hypertonique diminue CH2O de — 1,8±0,3 a —2,2±0,3 mi/mm
et augmente l'AVP urinaire de 8,24±2,75 a 20,28±l,94ng/
2 hr. II existe tine correlation hautement significative entre les
valeurs de C1120 et celles d'AVP urinaire (r= —0.66, N=26,
P<0.001). La correlation entre I'osmolalité plasmatique et
i'AVP urinaire est trés significative (r= 0.62, N= 26, P< 0.001) et
selon cette equation l'AVP commence a apparaltre dans les
urines pour une osmolalité plasmatique de 275.2 mOsm/kg.
Pendant la perfusion de serum sale hypertonique, la rénine
plasmatique (ARP) et l'adosterone plasmatique (AP) ont été
mesurées par méthodes radioimmunologiques. Alors que le
serum sale stimule la sécrétion de vasopressine, ii diminue I'ARP
et 1'AP. L'excrétion d'AVP mesurée par dosage radioimmuno-
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logique de 1'AVP urinaire répond aux modifications de l'osmola-
lité plasmatique qui affectent Ia sécrétion d'AVP, et refléte donc
avec precision Ia fonction neurohypophysaire. Les variations de
sécrétion de la refine et de 1'AVP sont dissociées pendant Ia
charge en sd.
Clinical investigation of antidiuretic hormone
(ADH) has been limited due to the fact that until
recently only biological assays have been available [1].
Radioimmunoassays, once their specificity has been
established, are simpler, more precise and permit the
handling of a greater number of samples. Several
radioimmunoassay systems have recently been re-
ported for ADH [2—11], and some of these have been
used for physiological studies of ADH in urine [3, 12,
13] or in plasma [14—20]. This report describes a
radioimmunological assay of ADH in human urine.
The utilization of a monoiodinated tracer purified by
affinity chromatography over porcine neurophysin
coupled to Sepharose permits a sensitivity of 0.75
picogram (pg)/mI. The specificity of the immunoassay
is demonstrated by immunological and biological
criteria. Results of studies of stimulation and inhibi-
tion of hormone production in response to osmotic
stimuli validate the assay method and permit the
establishment of normal urinary ADH concentrations
under controlled conditions.
Methods
Reagents. The antiserum (L289) used in this study
has been described previously [11]. In brief, lysine-8-
vasopressin (LVP) was coupled to albumin by carbo-
diimide, and five rabbits were immunized. Antibodies
with a suitable titer were obtained after six months in
four animals. One of these sera (L289) recognized
equally arginine-vasopressin (AVP) and LVP on a
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weight basis. Oxytocin, as well as angiotensin II, was
shown to have less than one-hundredth the affinity for
this antiserum as does AVP. A complete study of the
immunoreactivity of antiserum L289 by Czernikow,
Reinharz and Valloton [21] has shown that its reac-
tivity is directed towards the cyclic moiety of the
nonapeptide. The antiserum was diluted 1: 10 with
normal rabbit serum and stored in 1-mi aliquots at
—30°C.
Another antiserum used in this study was provided by
Dr. S. M. Giick (see Acknowledgments). This antiserum
has a different specificity since LVP has less than one-
third the affinity for this antiserum than does AVP.
Synthetic AVP was purchased from Sigma (Saint-
Louis, MO) and Ferring (Malmö, Sweden), with both
solutions having a biological activity of 400 lU/mg.
The synthetic LVP used had a biological activity of
270 lU/mg. Monoiodinated '5I-LVP was prepared by
iodinating LVP at low specific activity and by purify-
ing the tracer on a neurophysin Sepharose column as
described [22]. This procedure yields a monoiodinated
LYP that is homogenous on polyacrylamide gel
electrophoresis and has an immunologically deter-
mined specific activity of 1,750 iCi/g. lodination and
purification were performed each month, and 125J..
LVP was stored at —20°C.
The assay buffer contained 0.1 M Tris-HC1, pH 7.4,
and 2 mg/mI of crystalline bovine serum albumin
(Sigma, St. Louis, MO). Dextran-coated charcoal
solution, used to separate bound from free hormone,
was prepared by mixing 625 mg of charcoal and
62.5 mg of Dextran-T-70 (Pharmacia, Uppsala,
Sweden) in 100 ml of assay buffer. Rexyn H (100 to
200 mesh), used for urinary AVP extraction, was
purchased from the Fisher Company (Fair Lawn, NJ).
After removal of the fines, 500 g of resin was swollen
by successive addition of the following: 2 liters of
4N NaOH, I liter of H20, I liter of 2N HCI and 2
liters of H2O. The pH was then adjusted to 4.5 with
0.2M ammonium acetate, and the mixture was stored at
4°C.
Sample preparation. After micturition, urine samples
were immediately stored at —20°C. They were
extracted and assayed the same week, but they could
also be stored frozen at —20°C, pH 4.5, for up to
three months without any observed loss of immuno-
reactive AVP. A 10- to 20-mi sample of urine was
acidified to pH 4.5 with HC1 and passed over a l-ml
column of moist Rexyn packed in a plastic 5-mi
syringe. A slow and nearly constant flow rate was
obtained by placing a 0.80 x 25 mm gauge needle on
the syringe. After rinsing with 10 ml of ammonium
acetate buffer, pH 4.5, and 10 ml of 50% ethanol-
water, pH 4.5, AVP was eluted with 20 ml of 75%
ethanol-water, pH 2, into a 100-mi flask. The eluate
was evaporated at 35°C in a rotatory evaporator and
the dry residue was then redissolved in 2 ml of the
assay buffer.
Assay procedure. Standard curves were prepared in
triplicate by mixing 5 to 500 l of diluent containing
1.5 to 150 pg of standard AVP, 0.5 ml of a 1:50,000-
fold dilution of the L289 antiserum (prepared by
diluting the 1: 10 working stock 5,000-fold with
diluent) and 1 ml of diluent containing 3,000 cpm of
'25ILVP Correction for a final volume of 2 ml was
made with diluent prior to any addition. Unknowns
were assayed by addition of at least two different
amounts (from 10 to 400 d) of extract. All samples
were incubated in 10 x 75 mm disposable plastic tubes
at 4°C for five days. Then, 10 mm after addition of
0.4 ml of Dextran-coated charcoal solution, the tubes
were centrifuged at 3,000 rpm at 4°C for 15 mm. The
supernatant was discarded and the precipitate counted
in an automated deep-well gamma spectrometer for
10 mm (50% counting efficiency). Under these
conditions, the amount of tracer bound to the anti-
body in the absence of unlabelled hormone (B0) is
50%. The number of counts bound to the antibody was
expressed as a percentage of B0. For determinations
with Glick's antiserum, the following modifications
were made: final dilution of antiserum was 1:600,000;
0.1 to 10 pg of standard AVP was added; incubation
volume was 1 ml; and the extract was diluted 1: 10-fold
prior to assay.
Characterization of urinary A VP by polyacrylamide
gel electrophoresis. IJrinary AVP extract, standard
AVP and LVP were lyophilized and separately sub-
mitted to polyacrylamide gel electrophoresis at pH
3.7, 0°C, 12% acrylamide, system G [23]. Gels were
sliced transversally and slices were eluted with 0.5 ml
of 0.1 M Tris-HCL, pH 7.4. Fifty l aliquots of the
eluates were assayed for hormone content. Slices of
gels containing 1251-LVP were counted directly in a
gamma counter.
Clinical studies. Clinical studies were conducted on
normal male volunteers aged 25 to 35 yr who received
an ad lib intake of food and water the day before ex-
perimentation, with complete fluid restriction initiated
at 9 PM of the evening before the study. Two-hour urine
specimens were collected from recumbent subjects at
7 AM (control period). Six subjects were given water
load orally at 7 AM (15 mI/kg in 15 mm), and urine
specimens were collected at 9 and 11 AM. In four
subjects, infusion of 3% hypertonic saline solution
(7 mI/kg) was performed between 7 and 9 AM, and
urine specimens were collected at 9 AM. The subjects
were recumbent throughout the experimental pro-
cedure except to void urine. Just before voiding, blood
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was obtained by veinipuncture into heparinized tubes
and immediately centrifuged. Osmolality was deter-
mined on the fresh plasma and urine by freezing point
depression (Fiske osmometer, Uxbridge, MA). Uri-
nary sodium and potassium concentrations were
determined with a flame photometer (Instrument and
Laboratory Inc., Lexington, KY) and creatinine with
an autoanalyzer (Technicon, Tarrytown, NY). Plasma
renin activity and plasma aldosterone were measured
by radioimmunoassays described previously [24, 25].
Correlations were determined by linear regression
analysis using the method of least squares, and unless
specified, values are expressed SEM. Urinary ADH
values are not corrected for recoveries.
Results
Radioimmunoassay of A VP. Standard curve and
sensitivity. The minimum detectable dose, defined as
the dose 2 SD away from the mean of the zero dose
tubes [22], was 0.75 pg/mi with L289 antiserum. A
typical standard curve is shown in Fig. 1.
Recovery of A VP from urine. Recoveries were
performed by addition of increasing amounts of
standard AVP to urine specimens which had been
dialyzed for five days against distilled water containing
sodium (100 mEq/liter), potassium (50 mEq/liter) and
urea (15 g/liter). The values obtained are expressed in
Table I. The same recoveries were obtained with
'251-LVP. Changes in the urinary concentration of
Increasing % Recovery Increasing % Recovery
amounts of amounts of
AVP in 10 ml urine
of urine
100 pg (7) 87±1.6 10m1 to87
1,000 pg (6) 90.2± 2.2 20 ml 98—96.3
10,000 pg (6) 88±2.6 30 ml 89.9—100
1251-LVP:
50 pg (6) 89.9± 2.6 40 ml 101—105
urea, sodium and potassium had no effect on these
results.
Absence of blanks. The lack of significant blank
in the radioimmunoassay system is demonstrated by
the lack of interference of dialyzed urine specimens on
the binding of 1251-LVP to antibody (Fig. 1) and by
the results which are not dependent on the volume of
extract assayed (Table 2).
Reproducibility of the method. The overall inter-
assay coefficient of variation as calculated from eight
different assays of a human urine pooi, performed over
a three-month period is 8%. Values of urinary ADH
are not dependent on the time of storage (Table 2).
Specificity. To demonstrate that the immunoreactive
Table 2. Overall interassay coefficient of variationb
Date of assay Volume of extract assayed
lOOiil 2001
12/02/72 12 28
12/15/72 16 28.5
1/10/73 14.5 29.5
1/21/73 12 24.5
2/06/73 15.2 26.5
2/17/73 15.5 30
3/02/73 14.5 28
3/15/73 16.5 30
Table 1. Recovery of arginine-vasopressin (AVP) from urinea
Two left columns: Increasing amounts of standard vaso-
pressin were added to 10 ml of dialyzed urine aliquots and
assayed or counted for 1251-lysine-8-vasopressin (LVP). Paren-
theses indicate the number of experiments. Two right columns:
standard AVP was added to dialyzed urine to obtain a concen-
tration of 20 pg/mI, and different volumes were assayed in
duplicate.
90.
80.
70.
60
B/B0 50.
40
30
20.
10
Fig. 1. Standard curve. B/B0 (cpm bound over cpm bound at the
zero dose) is plotted vs. the log of the concentration of AVP, for
standard AVP (—); 20, 50, 100, 200, 400 l of urine extract(0—0); and for 100, 200 and 400 il of dialyzed urine (0—Eli).
'öis 1.5 3 7.5
AVP, pg/mi
a A pool of human urine was acidified to pH 4.5, divid-
_________
ed in 5-mi aliquots, stored frozen at —20°C and
30 75 assayed over a three-month period. The values read on
the standard curve are indicated for two different
amounts of each extract. Dependence on the volume of
extract and time of storage were tested by a two-way
analysis of variance (one observation per cell). The
overall interassay coefficient of variation (8%) was
calculated from these data for P <0.001.
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extract behaved as standard AVP, increasing amounts
of the same extract were assayed. As can be seen in
Fig. 1, the addition to the assay of 20 to 400 1 of
urinary extract displaces the antibody-bound 125j..
LVP in a curve parallel to that obtained by the
addition of standard AVP.
Another proof of the identity of the immunoreactive
extract with AVP was the fact that the urinary extract
had the same mobility as standard AVP on poly-
acrylamide gel electrophoresis. Its R1 is 0.64 at pH 3.7,
0°C (12% acrylamide), as opposed to R1 values of
0.62 and 0.69 for 1251-LVP and LVP under these
conditions.
Finally, comparison of urinary AVP was made in
two different immunoassay systems. AVP content of
nine urine specimens was measured in the extract with
both L289 and Glick's antiserum: values obtained were
identical in the two systems, as shown in Fig. 2.
Clinical studies. Oral water load in dehydrated
normal subjects increased C1120 from —1.4±0.12 to
2.53 0.66 mi/mm (first period after water load) and
0.26 0.48 mi/mm (second period) while urinary AVP
decreased from 7.82± 1.56 to 2.69±0.40 and 3.30±
0.61 ng/2 hr (Fig. 3). Infusion of hypertonic saline, on
the other hand, decreased C1120 from —1.79 0.36 to
—2.24 0.34 mi/mm and increased urinary AVP from
8.24 2.75 to 20.28 1.94 ng/2 hr (Fig. 4). The results
of the stimulation and suppression tests on plasma
osmolality (Posm), urinary osmolality (Uosm) and
urinary AVP are illustrated in Table 3. There is a
significant correlation between urinary AVP and
C1120 during the control period (r= —0.72, N=l0,
Cl
.0
0
0
I-
I.)
11
Urinary AVP (pg) determined with Glick's antibody
Fig. 2. Comparison of urinary A VP assayed with two different
antibodies. Regression line was calculated from the mean of
three values obtained from three different amounts of extract
assayed, using both antisera.
Fig. 3. Suppression test. Influence of orally administered water
load (15 mI/kg) on urinary AVP, C1120 urinary sodium and
potassium output. The mean is indicated in the middle and
lower parts of the figure by the horizontal line ( ).
P<0.02) in normal recumbent subjects who have
been water-deprived for ten hours. The correlation
between all the observed values for C1120 and urinary
AVP during these dynamic studies is highly significant
(r= —0.66, N=26, P<0.001), with a correlation
(r=0.62, N=26, P<0.OOl) between plasma osmo-
lality and urinary AVP as expressed by the following
equation:
AYP(flg/2 hr) 0.493 (Posm[mosmjkg] 275.2).
According to this equation, AVP appears in urine for a
plasma osmolality of 275.2 mOsm/kg. During these
studies, no significant variations in creatinine clear-
ance occurred, and the mean value was 114.2±4.6
ml/min.
While increasing AVP concentrations, the infusion
of hypertonic saline decreased plasma renin activity
from 2.33 to 0.91 0.13 ng/ml/3 hr (P<0.05)
and decreased plasma aidosterone from 5.4±0.84 to
3.0 ng/lOO ml (P<0.05).
U
°
water
load
r= 0.997
P<o.001
Y= I .02X —20.08
500
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Table 3. Stimulation-suppression test of urinary arginine-
vasopressin (AVP)a
Time of urin
collection
ary Posm Uosm
mOsm/kg mOsm/kg
AVP
ngf2 hr
Orally administered water load
5—7AM 293 908 11.16
7—9 279 128 2.16
9—11 282 276 4.41
5—7 AM 283 986 13.68
7—9 277 120 2.88
9—11 279 460 4.89
5—7 AM 294 1061 4.89
7—9 280 111 2.57
9—11 294 246 4.68
5—7 AM 297 1120 7.74
7—9 295 325 4,27
9—11 288 278 1.65
5—7 AM 289 965 4.40
7—9 285 178 2.19
9—11 284 357 2.15
5—7 AM 293 1200 5.04
7—9 288 182 2.07
9—11 289 168 2.07
5—7 AM
Saline infusion
298 990 16.32
7—9 301 940 22.98
5—7 AM 289 1050 4.86
7—9 303 980 20.60
5—7 AM 291 1220 7.13
7—9 295 1170 22.85
5—7 AM 295 1080 4.65
7—9 314 1010 14.70
a Effect of orally administered water load and saline infusion on
Posm, Uosm and urinary AVP.
Fig. 4. Stimulation test. Influence of iv. administered hypertonic
saline (3%, 7 ml/kg) on urinary AVP, C110 urinary sodium and
potassium output.
Discussion
The present study has been performed in order to
develop a radioimmunoassay of urinary AVP, to
validate the methodology and to establish very simple
stimulation-suppression tests which could be useful
for the investigation of AVP secretion under patho-
logical situations.
In order to obtain a sensitive radioimmunoassay, it
is necessary to use a tracer of high specific activity [261.
The tracer used in this study has a higher specific
activity, 1,750 sCi/g, than the previously reported
tracers [2—10]. However, the sensitivity thus ob-
tained is less than that obtained with Glick's anti-
serum, due to the difference in the affinity of these two
antisera. Using our monoiodinated tracer with Giick's
antiserum, the standardcurve is linear between 0.1
and 10 pg/mi, with a maximum sensitivity of around
2 pg/mi, whereas with L289, antiserum standard curves
currently used are between 0.75 and 75 pg/mI. For this
reason, an extraction and concentration of urine is
necessary before performance of a radioimmunoassay
using L289 antiserum. Nevertheless, this preliminary
step has several potential advantages. It increases the
specificity of the method by elimination of other
known or unknown peptides which could interfere
with AYP in the assay. It also eliminates salts and
urea which could have an unexpected influence on the
binding of 1251-LVP to antibody in some samples.
Thus, the increase in accuracy obtained by this pro-
cedure warrants the increased time of preparation.
Recovery of AVP from urine is complete and constant
from one sample to another under the conditions
described.
The material extracted from urine samples is
identical to AVP according to three criteria: 1)
I
>
z
0
a
U E
-r1
I-
a
a
Before After
saline saline
load load
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parallelism of assay curves with either extract or
standard AVP; 2) same electrophoretic mobility of the
extract as standard AVP; and 3) identity of urinary
AVP values found using either L289 antiserum or
Glick's antiserum. This last point is of importance
since these two antisera have different specificities.
LVP has less than one-third the affinity for Glick's
antiserum than AVP does, even though both have
similar biological properties and differ only by the
substitution of lysine for arginine in position 8 of the
molecule [14]. With the L289 antiserum, the cyclic
moiety of the molecule is recognized, and LVP has
the same reactivity as AVP [211. Despite these differ-
ences, the same values as urinary AVP were obtained
in a comparative radioimmunoassay study. Moreover,
the mean value of urinary AVP after 10 hr of water
deprivation (7.89 1.59 ng/2 hr) is in very close
agreement with the results of Miller and Moses, who
found 9.70 ng/2 hr after 16 hr of fluid deprivation [13].
One advantage of assaying AVP in urine is that
samples are unaffected by storage up to three months
[14]. Another advantage is that a cumulative excretion
is measured for a given interval of time, whereas a
plasma assay gives only an instantaneous picture of
AVP production. It has the possible disadvantage of
being more dependent on a change in renal metabolism
induced simultaneously with a change in AVP secre-
tion [27]. However, the constancy of creatinine clear-
ance eliminates any changes of AVP excretion due to
variations of glomerular filtration rate. Neverthdess,
the validity of using the present radioimmunoassay of
urinary AVP as a means of investigating AVP secre-
tion is supported by the clinical results obtained.
Orally administered water loads and i.v. administered
hypertonic saline have induced the expected changes.
The increase in C1120 is accompanied by decreased
urinary AVP, and the decrease in CH2O by an increase
in urinary AVP. The amounts of ingested water
(15 ml/kg) and infused saline (7 mi/kg) that were
chosen are less than those in the classical tests generally
used to investigate AVP secretion by means of induced
changes in C20 and TCH0. It is therefore expected that
the application of these stimulation-suppression tests
to the investigation of pathological situations will be
easier than with the tests previously used, and that they
will be sufficiently sensitive to detect an abnormality
in AVP secretion. Under these well-controlled condi-
tions, the correlation between urinary AVP and CH20
is highly significant. Such a correlation between
urinary AVP and CH20 was not found in previous
studies using 24-hr urinary AVP collections [13]. This
lack of correlation was probably due to the multipli-
city of factors which are able to influence AVP release
during a 24-hr period; posture, smoking, sympathetic
nervous system activity, drinking and eating habits
etc.
With the results obtained, it has been possible to
calculate a regression line between urinary AVP and
plasma osmolality and to estimate the plasma
osmolality for which AVP appears in urine. This
osmolality, which is 275.2 mOsm/kg under normovo-
lemic and normotensive conditions, is only an estima-
tion since it is possible that at the initiation of ADH
release the correlation between Posm and AVP may
not be a straight-line relationship. Miller and Moses
[28], by oral water deprivation in water-loaded sub-
jects, found an osmotic threshold of 282±2 mOsm/kg.
Robertson et al [14], by correlating plasma AVP with
plasma osmolality, found that the osmoreceptor
governing AVP release has a threshold of 280 mOsm/
kg. Thus, the estimated plasma osmolality for which
AVP appears in urine is slightly below the reported
values of osmotic threshold for vasopressin release.
However, in the previously reported correlation
between Posm and AVP [14], certain very low plasma
AVP concentrations and their correspondingly low
plasma osmolalities were not included.
The increase in osmolality is the most well-known
stimulation for AVP release, but the importance of the
decrease in extraceiluiar fluid volume has been clearly
demonstrated [29]. The stimulation test is a situation
in which changes in volume and osmolality are able to
influence AVP in an opposite direction. The increase in
volume could decrease AVP, while increase in
osmolality could stimulate AVP. In this situation, the
osmolar stimulus is the most efficient, and AVP
increases despite the expansion of extracellular fluid
volume. By contrast, plasma values of renin activity
and aldosterone are depressed by positive sodium
balance. Even if the renin-angiotensin system plays a
role in AVP release under certain conditions [30]. AVP
is released in the presence of decreased renin secretion
after infusion of hypertonic saline.
In conclusion, radioimmunoassay of urinary AVP, in
conjunction with the previously described radio-
immunoassay for renin [24] and aldosterone [25],
makes possible a more complete investigation of the
hormonal control of sodium and water metabolism.
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